Laminate composites behavior under quasi-static and high velocity perforation

M.H. Pol,E. Mehrabani Yeganeh,G. H. Liaghat 국제구조공학회 2016 Steel and Composite Structures, An International J Vol.22 No.4

In this paper, the behavior of woven E-glass fabric composite laminate was experimentally investigated under quasi-static indentation and high velocity impact by flat-ended, hemispherical, conical (cone angle of 37° and 90°) and ogival (CRH of 1.5 and 2.5) cylindrical perforators. Moreover, the results are compared in order to explore the possibility of extending quasi-static indentation test results to high velocity impact test results in different characteristics such as perforation mechanisms, performance of perforators, energy absorption, friction force, etc. The effects of perforator nose shape, nose length and nose-shank connection shapes were investigated. The results showed that the quasi-static indentation test has a great ability to predict the high velocity impact behavior of the composite laminates especially in several characteristics such as perforation mechanisms, perforator performance. In both experiments, the highest performance occurs for 2.5 CRH projectile and the lowest is related to blunt projectiles. The results show that sharp perforators indicate lower values of dynamic enhancement factor and the flat-ended perforator represents the maximum dynamic enhancement factor among other perforators. Moreover, damage propagation far more occurred in high velocity impact tests then quasi-static tests. The highest damage area is mostly observed in ballistic limit of each projectile which projectile deviation strongly increases this area.

HCV : PE-135 ; Boceprevir plus peginterferon/ribavirin for the treatment of HCV/HIV co-infected patients: End of treatment (WEEK 48) interim results

( J Mallolas ),( S Pol ),( A Rivero ),( H Fainboim ),( C Cooper ),( J Slim ),( S Thompson ),( J Wahl ),( W Greaves ),( M Sulkowski ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.1

Background: Addition of boceprevir (BOC) to peginterferon (P) and ribavirin (R) significantly increases SVR among HCVmonoinfected patients for whom SVR rates have been low. The objective of this phase 2 trial was to investigate the efficacy and safety of BOC+P/R in HCV/HIV-coinfected patients. Methods: In this multicenter, double-blind, international trial, patients with untreated hepatitis C genotype 1 infections and HIV RNA <50 copies/mL were randomized 2:1 to receive P (PEG 2b 1.5 ug/kg/wk)/R (600-1400 mg/day, by weight) + BOC 800mg TID or P/R+placebo for 44 weeks, after a 4-week lead-in of P/R. NNRTIs, zidovudine, or didanosine were not permitted. Patients were stratified by: cirrhosis/fibrosis (yes vs. no) and baseline HCV-RNA (<800,000 IU/mL vs ≥800,000 IU/mL). The primary efficacy endpoint was SVR, undetectable plasma HCV-RNA 24 weeks after end of treatment (EOT). Secondary endpoints and planned interim analyses included proportion of subjects with undetectable HCV-RNA at treatment week (TW) 4, 8, 12, 24 and 48/EOT. Results: 100 patients were randomized between 11/2009 and 12/2010; 2 patients in the BOC arm did not receive medication; thus, 34 control and 64 experimental patients were treated. The majority were non-cirrhotic (95%), white (82%), male (69%) with median age ~43 years. Most had high baseline HCV-RNA (88%) and HCV genotype 1a (65%). At TW48/EOT, the rate of undetectable HCV-RNA was 63.9% and 29.4% in the BOC and control arms, respectively (Table). 61% of the BOC group and 32% of the control group completed 48 weeks of treatment; 20% and 9%, respectively, discontinued due to adverse events. HCV treatment failure occurred in 9% of the BOC group and 53% of the control group. BOC patients were more likely than controls to have decreased appetite, pyrexia, dysgeusia, vomiting, asthenia, anemia, and neutropenia. By TW48, 2 patients in the BOC group and 3 in the control group had HIV virologic failure. Conclusion: The addition of BOC to P/R was associated with higher rates of undetectable HCV-RNA at all time points, including TW48/EOT. The safety and tolerability profile was consistent with that observed in HCV-monoinfected patients. PE-136 Sustained virologic response (SVR) in prior peginterferon/ribavirin (PR) treatment failures after retreatment with boceprevir (BOC) + PR: The PROVIDE study interim results JP Bronowicki1, M Davis2, S Flamm3, S Gordon4, E Lawitz5, E Yoshida6, J Galati7, V Luketic8, J McCone9, I Jacobson10, P Marcellin11-12, A Muir13, F Poordad14, LD Pedicone15, W Deng15, M Treitel15, J Wahl15, J Vierling16 1University Henri Poincare of Nancy, Vandoeuvre-les-Nancy, France; 2South Florida Center of Gastroenterology, Wellington, FL, USA; 3Northwestern Feinberg School of Medicine, Chicago, IL, USA; 4Henry Ford Hospital, Detroit, MI, USA; 5Alamo Medical Research, San Antonio, TX, USA; 6University of British Columbia and Vancouver General Hospital, Vancouver, BC, Canada; 7Liver Specialists of Texas, Houston, TX, USA; 8Virginia Commonwealth University School of Medicine, Richmond, VA, USA; 9Mt. Vernon Endoscopy Center, Alexandria, VA, USA; 10Weill Cornell Medical College, New

HCV, Alcoholic : PE-135 ; Boceprevir plus peginterferon/ribavirin for the treatment of HCV/HIV co-infected patients: End of treatment (WEEK 48) interim results

( J Mallolas ),( S Pol ),( A Rivero ),( H Fainboim ),( C Cooper ),( J Slim ),( S Thompson ),( J Wahl ),( W Greaves ),( M Sulkowski ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.-

Background: Addition of boceprevir (BOC) to peginterferon (P) and ribavirin (R) significantly increases SVR among HCV- monoinfected patients for whom SVR rates have been low. The objective of this phase 2 trial was to investigate the efficacy and safety of BOC+P/R in HCV/HIV-coinfected patients. Methods: In this multicenter, double-blind, international trial, patients with untreated hepatitis C genotype 1 infections and HIV RNA <50 copies/mL were randomized 2:1 to receive P (PEG 2b 1.5 ug/kg/wk)/R (600-1400 mg/day, by weight) + BOC 800mg TID or P/R+placebo for 44 weeks, after a 4-week lead-in of P/R. NNRTIs, zidovudine, or didanosine were not permitted. Patients were stratified by: cirrhosis/fibrosis (yes vs. no) and baseline HCV-RNA (<800,000 IU/mL vs ≥800,000 IU/mL). The primary efficacy endpoint was SVR, undetectable plasma HCV-RNA 24 weeks after end of treatment (EOT). Secondary endpoints and planned interim analyses included proportion of subjects with undetectable HCV-RNA at treatment week (TW) 4, 8, 12, 24 and 48/EOT. Results: 100 patients were randomized between 11/2009 and 12/2010; 2 patients in the BOC arm did not receive medication; thus, 34 control and 64 experimental patients were treated. The majority were non-cirrhotic (95%), white (82%), male (69%) with median age ~43 years. Most had high baseline HCV-RNA (88%) and HCV genotype 1a (65%). At TW48/EOT, the rate of undetectable HCV-RNA was 63.9% and 29.4% in the BOC and control arms, respectively (Table). 61% of the BOC group and 32% of the control group completed 48 weeks of treatment; 20% and 9%, respectively, discontinued due to adverse events. HCV treatment failure occurred in 9% of the BOC group and 53% of the control group. BOC patients were more likely than controls to have decreased appetite, pyrexia, dysgeusia, vomiting, asthenia, anemia, and neutropenia. By TW48, 2 patients in the BOC group and 3 in the control group had HIV virologic failure. Conclusion: The addition of BOC to P/R was associated with higher rates of undetectable HCV-RNA at all time points, including TW48/EOT. The safety and tolerability profile was consistent with that observed in HCV-monoinfected patients.

A Long-Term, Observational, Follow-Up Study of Patients Treated in Phase 2 and 3 Clinical Studies with Daclatasvir- Based Regimens: Efficacy and Safety Outcomes

( KR Reddy ),( S Pol ),( PJ Thuluvath ),( H Kumada ),( J Toyota ),( K Chayama ),( J Levin ),( E Lawitz ),( A Gadano ),( W Ghesquiere ),( G Gerken ),( M Brunetto ),( CY Peng ),( M Silva ),( S Strasser 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1

Background/aims: Daclatasvir plus other direct-acting antivirals (DAAs) and/or peg-interferon/ribavirin has achieved high rates of sustained virologic response (SVR) in multiple clinical studies of patients. This follow-up study evaluates the long-term efficacy and safety outcomes in these patients. Methods: : This 144-week observational study enrolled patients treated with ≥ 1 dose of daclatasvir within 6 months of either completing their parent studies or protocol availability at the study site. The study objectives were to evaluate SVR12 durability, persistence of emergent NS5A and NS3 substitutions in non-responders, and to characterize events of hepatic disease progression or hepatocellular carcinoma. Results: This study enrolled 1503 patients treated with DAA-only (n = 893) or interferon-containing (n = 610) regimens of daclatasvir, of whom 60% were male, 18% were aged ≥ 65 years, 87% had HCV genotype 1 infection, and 18% had cirrhosis. Overall, 1329/1489 evaluable patients archived SVR12 in parent studies; 1316 (99%) maintained SVR until their most recent follow-up visit. 12 responders relapsed after achieving SVR12 (9 on/before and 3 after post-treatment week 24); 1 was re-infected. Relapse occurred in 3/842 (0.4%) and 9/487 responders (2%) treated with DAA-only regimens and interferon-containing regimens, respectively. From parent study end of treatment, hepatic disease progression (n = 15) or new hepatocellular carcinoma (n = 23) were diagnosed in 36 patients (two had both); median time to diagnosis was 70 weeks (range, 0.4-206 weeks). These 36 patients were generally older (median, 61 years versus 56 years), more had cirrhosis at baseline (50% versus 18%), and most were infected with HCV genotype 1a (36%) or 1b (61%). Complete replacement of emergent NS5A, NS3 substitutions by wild-type sequences was observed in 27/157 (17%), 35/47 (74%) non-responders, respectively. Conclusions: The results suggest that SVR12 achieved with daclatasvir- based regimens is durable in the long term. Hepatic disease progression events and new hepatocellular carcinoma were infrequent.

^(237)Np(n,f) Cross Section: New Data and Present Status

C. Paradela,L. Tassan-Got,L. Audouin,B. Berthier,L. Ferrant,S. Isaev,C. Le Naour,C. Stephan,D. Trubert,S. David,I. Duran,D. Tarrio,H. Alvarez-Pol,U. Abbondanno,K. Fujii,P. M. Milazzo,C. Moreau,G. Aert 한국물리학회 2011 THE JOURNAL OF THE KOREAN PHYSICAL SOCIETY Vol.59 No.23

In this document, we present the final result obtained at the n_TOF experiment for the neutron-induced fission cross section of the ^(237)Np, from the fission threshold up to 1 GeV. The method applied to get this result is brie y discussed. n_TOF data are compared to the last experimental measurements using other TOF facilities or the surrogate method, reported experiments performed with monoenergetic sources and the FISCAL systematic, including a discussion about the existing discrepancies.

High-energy Neutron-induced Fission Cross Sections of Natural Lead and Bismuth-209

D. Tarrio,L. Tassan-Got,L. Audouin,B. Berthier,L. Ferrant,S. Isaev,C. Le Naour,C. Stephan,D. Trubert,S. David,I. Duran,C. Paradela,H. Alvarez-Pol,U. Abbondanno,K. Fujii,P. M. Milazzo,C. Moreau,G. Aert 한국물리학회 2011 THE JOURNAL OF THE KOREAN PHYSICAL SOCIETY Vol.59 No.23

The CERN Neutron Time-Of-Flight (n_TOF) facility is well suited to measure small neutron-induced fission cross sections, as those of subactinides. The cross section ratios of ^(nat)Pb and ^(209)Bi relative to ^(235)U and ^(238)U were measured using PPAC detectors. The fragment coincidence method allows to unambiguously identify the fission events. The present experiment provides the first results for neutron-induced fission up to 1 GeV for ^(nat)Pb and ^(209)Bi. A good agreement with previous experimental data below 200 MeV is shown. The comparison with proton-induced fission indicates that the limiting regime where neutron-induced and proton-induced fission reach equal cross section is close to 1 GeV.